MMCAP Contract order for nutritional supplements

McKesson has been awarded a contract (HHSTX-6-0000382622) through the MMCAP (Multistate Medication Cooperative Purchasing Agreement) for pharmaceutical and allergenic extract procurement in Texas, effective August 14, 2025. The contract encompasses five distinct UNSPSC-coded products, including allergenic extracts such as Alfalfa, Horse Epithelium, and Rabbit Epithelium extracts, as well as pharmaceutical products Vestronidase alfa and Naloxegol.

The contract is categorized under NIGP Code 26972 for Miscellaneous Drugs and Pharmaceuticals, indicating a broad pharmaceutical supply arrangement. While specific contract value details are not provided, the award suggests McKesson will serve as the prime contractor supplying these specialized medical products to Texas state healthcare entities. The MMCAP framework typically enables participating states to leverage collective purchasing power for pharmaceutical and medical supply acquisitions, potentially offering cost efficiencies and standardized procurement processes.